$9.10
1.83% today
Nasdaq, Apr 04, 09:16 pm CET
ISIN
US14070B1017
Symbol
CAPR
Sector
Industry

Capricor Therapeutics, Inc. Stock price

$9.27
-4.40 32.19% 1M
-7.80 45.69% 6M
-4.53 32.83% YTD
+2.47 36.32% 1Y
+5.55 149.19% 3Y
+8.27 827.00% 5Y
-74.23 88.90% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.47 4.83%
ISIN
US14070B1017
Symbol
CAPR
Sector
Industry

Key metrics

Market capitalization $423.42m
Enterprise Value $276.73m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 12.43
P/S ratio (TTM) P/S ratio 19.01
P/B ratio (TTM) P/B ratio 2.90
Revenue growth (TTM) Revenue growth -11.55%
Revenue (TTM) Revenue $22.27m
EBIT (operating result TTM) EBIT $-42.56m
Free Cash Flow (TTM) Free Cash Flow $-41.53m
Cash position $151.52m
EPS (TTM) EPS $-1.20
P/E forward negative
P/S forward 5.94
EV/Sales forward 3.88
Short interest 22.56%
Show more

Is Capricor Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Capricor Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Capricor Therapeutics, Inc. forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Capricor Therapeutics, Inc. forecast:

Buy
100%

Financial data from Capricor Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
22 22
12% 12%
100%
- Direct Costs 1.43 1.43
35% 35%
6%
21 21
14% 14%
94%
- Selling and Administrative Expenses 13 13
18% 18%
57%
- Research and Development Expense 49 49
36% 36%
221%
-41 -41
80% 80%
-185%
- Depreciation and Amortization 1.43 1.43
35% 35%
6%
EBIT (Operating Income) EBIT -43 -43
78% 78%
-191%
Net Profit -40 -40
82% 82%
-182%

In millions USD.

Don't miss a Thing! We will send you all news about Capricor Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Capricor Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
16 days ago
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ET Company Participants A.J. Bergmann - Chief Financial Officer Linda Marban - Chief Executive Officer Conference Call Participants Edward Tenthoff - Piper Sandler Leland Gershell - Oppenheimer Joseph Pantginis - H.C.
Neutral
GlobeNewsWire
16 days ago
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided a corporate update.
Neutral
GlobeNewsWire
18 days ago
--Preservation of Skeletal Muscle Function Shown Over 3 Years Resulting in 52% Slowing of Disease-- --Data Presented at the 2025 Muscular Dystrophy Association (MDA) Conference--
More Capricor Therapeutics, Inc. News

Company Profile

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.

Head office United States
CEO Linda Marbán
Employees 160
Founded 1996
Website www.capricor.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today